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SYMPOS IUM REPORT
Disrupted in schizophrenia 1 and phosphodiesterase 4B:
towards an understanding of psychiatric illness
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Disrupted in schizophrenia 1 (DISC1) is one of the most convincing genetic risk factors for major
mental illness identified to date. DISC1 interacts directly with phosphodiesterase 4B (PDE4B), an
independently identified risk factor for schizophrenia. DISC1–PDE4B complexes are therefore
likely to be involved in molecular mechanisms underlying psychiatric illness. PDE4B hydrolyses
cAMP and DISC1 may regulate cAMP signalling through modulating PDE4B activity. There is
evidence that expression of both genes is altered in some psychiatric patients. Moreover, DISC1
missense mutations that give rise to phenotypes related to schizophrenia and depression in mice
are located within binding sites for PDE4B. These mutations reduce the association between
DISC1 and PDE4B, and one results in reduced brain PDE4B activity. Altered DISC1–PDE4B
interaction may thus underlie the symptoms of some cases of schizophrenia and depression.
Factors likely to influence this interaction include expression levels, binding site affinities and
the DISC1 and PDE4 isoforms involved. DISC1 and PDE4 isoforms are targeted to specific
subcellular locations which may contribute to the compartmentalization of cAMP signalling.
Dysregulated cAMP signalling in specific cellular compartments may therefore be a predisposing
factor for major mental illness.
(Received 6 July 2007; accepted after revision 31 August 2007; first published online 6 September 2007)
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Schizophrenia is a devastating illness characterized by
profound emotional and cognitive disturbances. It is a
multifactorial disorder believed to arise, in part, from the
actions of multiple genetic variants that influence brain
development and function. There is some evidence for
clinical and therapeutic overlap between schizophrenia
and mood disorders such as bipolar disorder and severe
recurrent depression, although this remains a controversial
area (for review see Maier et al. 2006), and indeed
many genetic loci have been implicated in conferring
susceptibility to both schizophrenia and affective disorders
(for review see Blackwood et al. 2007). One such
candidate is the Disrupted in schizophrenia (DISC)
locus which was first implicated in psychiatric illness
This report was presented at a symposium on Compartmentalized
signalling in neurons, which took place at the Life Sciences 2007 meeting,
9–10 July 2007, Glasgow, UK.
by our studies of a large Scottish family in which a
balanced t(1;11) chromosomal translocation cosegregates
significantly with schizophrenia, bipolar disorder and
severe recurrent depression (Blackwood et al. 2001).
This translocation directly disrupts two overlapping genes
named DISC1 and DISC2 on chromosome 1 (Millar et al.
2000), and statistical analysis indicates that inheritance of
the translocation is causal in this family (Blackwood et al.
2001). Thus disruption of these genes is likely to generate
the risk of severe mental illnesses in translocation carriers.
Since its identification as a genetic risk factor for
major mental illness, the DISC locus has been implicated
in causing schizophrenia, bipolar disorder and unipolar
depression in multiple populations worldwide, although
these studies highlight different regions and no definitive
functional variants have yet been found (for review see
Porteous et al. 2006). The DISC locus is consequently now
regarded as a highly convincing candidate for psychiatric
illness. Moreover, genetic variants at this locus have been
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associated with cognitive functions in both affected and
unaffected individuals, as well as with influences on
hippocampal structure and function, and grey matter
volume (for review see Porteous et al. 2006). The
DISC genes are therefore plausible genetic and biological
candidates for causing susceptibility to major mental
illness and it is now essential to discover the mechanism
by which this occurs.
DISC1 encodes multiple isoforms with no significant
homology to other proteins. Primary sequence analysis of
the full-length ∼100 kDa isoform indicates the presence
of a head domain with no clear structure, and a long
helical tail domain containing multiple regions with high
coiled-coil forming potential (Millar et al. 2000). DISC1
therefore has structural similarity to other proteins termed
molecular scaffolds, and studies of its very large number
of potential binding partners indicate that DISC1 may
indeed act as an assembly point for functional multiprotein
complexes. DISC2, however, lacks any obvious coding
potential and is suggested to belong to the class of antisense
RNA genes that act as regulators of sense gene expression
(Millar et al. 2000), although there is as yet no experimental
data to support this speculation.
Most work to date has focused upon DISC1, and as
part of the drive to identify its function and mechanism
of involvement in psychiatric illness, many studies have
concentrated upon identification of DISC1 interacting
proteins. Numerous DISC1 binding partners involved in
many cellular functions have been identified, including
LIS1 and NDEL1, which implicate DISC1 in the process
of neuronal migration within the developing brain (for
review see Mackie et al. 2007). Another binding partner is
phosphodiesterase 4B (PDE4B) identified in a large-scale
yeast two-hybrid screen that identified a substantial
number of potential interactors (Camargo et al. 2007).
PDE4B was selected for detailed follow-up because it had
been independently identified as a risk factor through
our studies of another Scottish family with a t(1;16)
chromosomal translocation (Millar et al. 2005). This trans-
location was inherited by cousins, one diagnosed with
schizophrenia and the other with a psychotic disorder, and
directly disrupts PDE4B on chromosome 1, as well as the
gene encoding cadherin 8 (CDH8) on chromosome 16
(Millar et al. 2005). PDE4B has subsequently been further
implicated as a genetic risk factor (Pickard et al. 2007).
This interaction between two independently identified risk
factors suggests that we have identified a pathway that
is likely to directly contribute to the symptoms of severe
psychiatric disorders.
PDE4B is an excellent biological candidate in its own
right. It belongs to a family of four genes (PDE4A-D) that
act to hydrolyse cAMP and switch off cAMP signalling
cascades (for review see Houslay & Adams, 2003). PDE4s
are orthologous to the Drosophila melanogaster Dunce
gene, which has a critical role in synaptic plasticity,
and learning and memory (for review see Davis, 1996).
Moreover inhibitors of PDE4 activity influence NMDA
receptor-dependent memory (for review see Mackie et al.
2007), while the PDE4 inhibitor rolipram additionally has
an antidepressant (for review see Houslay & Adams, 2003)
and antipsychotic-like (Kanes et al. 2007) profile. Mice
deficient in PDE4B and PDE4D have been generated and
both lines (untreated) behave similarly to wild-type mice
that have been treated with antidepressants (O’Donnell
& Zhang, 2004). Finally, several studies have reported that
antidepressant treatments up-regulate expression of PDE4
isoforms in rodent brain (for review see Mackie et al. 2007).
These observations are all consistent with an involvement
of PDE4B and other PDE4s in molecular mechanisms that
underlie psychiatric disorders.
Through the use of alternative promoters and first
exons, the four PDE4 genes encode more than 20 different
isoforms, with five separate PDE4B isoforms identified
to date (for review see Houslay & Adams, 2003; Cheung
et al. 2007). PDE4s have a conserved modular structure
consisting, in long isoforms, of a C-terminal catalytic
domain linked to two regulatory regions termed upstream
conserved regions 1 and 2 (UCR1 and UCR2, for review
see Houslay & Adams, 2003). In addition each PDE4
isoform has a unique N-terminal domain that is believed
to confer targeting to specific subcellular compartments
(for review see Houslay & Adams, 2003). Specific
isoforms are therefore likely to occupy restricted sub-
cellular locations and this, together with the presence of
factors such as A kinase anchoring proteins (AKAPs), is
believed to underpin compartmentalized cAMP signalling
within cells.
Interaction between DISC1 and PDE4B has been
confirmed, and in addition DISC1 has been shown to
bind isoforms from each PDE4 family (Millar et al.
2005; Murdoch et al. in press). PDE4 association with
DISC1 involves the common regulatory UCR2 domain,
suggesting that DISC1 may have a role in modulating
PDE4 catalytic activity (Millar et al. 2005). Moreover,
in the human neuroblastoma cell line SH-SY5Y, the
71 kDa isoform of DISC1 has been shown to associate
dynamically with PDE4B, with the complex dissociating
in response to elevated cAMP levels in a protein kinase A
(PKA)-dependent manner (Millar et al. 2005). Under these
same conditions PDE4B becomes PKA phosphorylated
and its catalytic activity increases (Millar et al. 2005). This
led to a hypothetical model whereby DISC1 sequesters
PDE4B in a low activity form until it is required to switch
off cAMP signalling, whereupon PDE4B is released from
DISC1 in a high activity form.
Subsequent work has revealed that this model is too
simplistic, since dissociation in response to elevated cAMP
is dependent upon specific DISC1 and PDE4 isoforms, and
some isoform combinations do not dissociate (Murdoch
et al. 2007). Specifically, full-length 100 kDa DISC1
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dissociates from PDE4C and PDE4D isoforms, but not
from PDE4A or PDE4B isoforms, while the shorter 71 kDa
DISC1 isoform does dissociate from PDE4B (Millar et al.
2005; Murdoch et al. 2007). The basis for the differential
responses of specific isoforms to elevated cAMP may
relate to the number of contact sites between DISC1
and PDE4. A peptide array strategy revealed that there
are in fact five PDE4 binding sites on DISC1 (Murdoch
et al. 2007). Three of these binding sites are specific for
PDE4B isoforms, while two potentially bind isoforms
from each PDE4 family (Murdoch et al. 2007) and it is
therefore possible that 100 kDa DISC1 binds stably to
PDE4B because of these additional points of contact, while
in the 71 kDa form of DISC1, whose amino acid content
has yet to be determined, some of the binding sites may
be absent, allowing dissociation to occur. Although the
complexities of the DISC1–PDE4 interaction are not yet
understood, there is clearly potential for dysregulation of
cAMP signalling cascades via altered interaction between
these proteins.
The search is now on for evidence that there is indeed
dysregulation of DISC1 and PDE4 in psychiatric patients.
In lymphoblastoid cell lines derived from family members
carrying the t(1;11) translocation that disrupts DISC1,
it has been shown that DISC1 expression is reduced to
approximately half normal levels suggesting that there is
no protein expressed from the disrupted allele (Millar
et al. 2005). DISC1 haploinsufficiency is therefore likely
to underlie the risk of psychiatric illness in individuals
carrying this translocation. Consistent with this, DISC1
expression is reportedly reduced in lymphoblastoid cell
lines from unrelated bipolar disorder patients (Maeda et al.
2006). However, studies of postmortem brain have yet
to reveal significantly altered DISC1 expression levels in
the limited number of psychiatric patients studied so far
(Lipska et al. 2006). The t(1;16) translocation that disrupts
PDE4B has not yet been fully investigated, but the PDE4B1
isoform is reduced in a lymphoblastoid cell line from these
patients (Millar et al. 2005). Overall, then, there is evidence
that altered expression of both DISC1 and PDE4B is related
to the presence of psychiatric symptoms.
Studying dysregulated DISC1–PDE4 interactions in
psychiatric patients is complicated by many factors
including tissue availability, lifetime drug treatment and
other co-morbidities. Mouse models will therefore provide
an alternative means to investigate the involvement of
DISC1 and PDE4 in molecular mechanisms that cause
psychiatric disorders. A natural DISC1 mutation in all
129 strains of mice was discovered recently (Koike et al.
2006; Clapcote & Roder, 2006). A deletion within exon
6 introduces a premature stop codon and is therefore
predicted to abolish normal DISC1 protein expression.
Unexpectedly however, the majority of DISC1 isoforms
are apparently expressed as usual (Ishizuka et al. 2007)
possibly due to an exon-skipping mechanism. A modified
version of the 129 DISC1 allele carrying an artificial
stop codon in exon 8, and downstream polyadenylation
signal, reportedly results in cognitive defects related
to schizophrenia when transferred to a C57BL/6 J
background. Two ethyl nitrosourea-induced DISC1
mutations have also been reported (Clapcote et al. 2007).
These missense mutations are a change of glutamine to
leucine at position 31 (Q31L), and a leucine to proline at
position 100 (L100P). Detailed analysis revealed that the
Q31L and L100P mutations result in phenotypes related to
depression and schizophrenia, respectively, using measures
designed to correlate in mice with clinical manifestations
of these illnesses (Clapcote et al. 2007). The intriguing
differences in the phenotypes resulting from these two
mutations add further weight to the evidence that DISC1
is a risk factor for both schizophrenia and depression, and
indicate that different types of mutations within this gene
may cause susceptibility to major mental illness.
Both missense mutations are located within PDE4B-
specific binding sites, and both reduce binding between
DISC1 and PDE4B in overexpression systems, with the
L100P mutation having the greater effect (Clapcote et al.
2007). This suggests that altered DISC1–PDE4B binding
does indeed confer risk of developing psychiatric illness.
Although interaction between DISC1 and PDE4B has
yet to be demonstrated in the brain, in Q31L mutants
brain PDE4B activity is also reduced, most likely as a
direct effect of the mutation upon PDE4B association with
DISC1 (Clapcote et al. 2007). Reduced PDE4B activity
may therefore be a contributory factor in some human
cases of depression. This reduced PDE4B catalytic activity
of Q31L mutants is apparently at odds with the model
proposing that PDE4B exists in a high activity form when
not associated with DISC1, implying that the mechanism
by which this mutation reduces DISC1–PDE4B association
is not related to the sequence of events leading to
cAMP-induced PDE4B dissociation from DISC1, and
concomitant PDE4B activation. These initial biochemical
observations require substantial additional effort to dissect
out the pathways by which the missense DISC1 mutations
lead to the observed behavioural and pharmacological
phenotypes, with PDE4B being just one of the many DISC1
binding partners awaiting investigation.
In summary, a complex picture is now emerging
whereby DISC1 modulates cAMP signalling through
its association with PDE4s. Many factors are likely to
influence this interaction, including which DISC1 and
PDE4 isoforms are involved, their expression levels and
their binding site affinities. Studies of psychiatric patients
and mouse models suggest that any functional variation
affecting these factors may confer risk of developing
major mental illness. It is now important to discover
which molecular pathways and central nervous system
functions are regulated by DISC1–PDE4 interaction and
which are dysfunctional in human psychiatric illness. The
C© 2007 The Authors. Journal compilation C© 2007 The Physiological Society
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former will be determined in part by which additional
proteins are associated with, and modulated by, the cAMP
signalling cascades governed by DISC1–PDE4 complexes,
and such proteins are likely to include some of those
identified as potential DISC1 binding partners in yeast
two-hybrid screens. An additional critical factor will be
compartmentalization of these protein complexes, since
specific isoforms of both DISC1 and PDE4 are targeted
to particular subcellular compartments including the
centrosome, nucleus and mitochondrion (Millar et al.
2005; for review see Mackie et al. 2007; James et al.
2004; Lynch et al. 2006). Consequently there is potential
for DISC1–PDE4 complexes to modulate aspects of the
function of several organelles. There is also evidence
that DISC1 and PDE4 isoforms are both present at
neuron-specific sites such as synapses (Clapcote et al. 2007;
Kirkpatrick et al. 2006), raising the intriguing possibility
that cAMP signalling downstream of synaptic receptors
may be abnormal in some psychiatric patients.
DISC1–PDE4 complexes may thus offer new prospects
for therapeutic intervention in psychiatric illness.
Rolipram has antidepressant and antipsychotic-like action
through inhibition of PDE4 activity, indicating that it
may be possible to treat psychiatric disorders by directly
modulating PDE4-specific cAMP hydrolysis. DISC1 inter-
action with the PDE4 family of isoforms may therefore
offer an exciting new opportunity to provide better
treatment for severe and disabling psychiatric illness.
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